Lubrijoint PLus

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lubrijoint PLus

Quick Facts

Property Description
Active ingredient Glucosamine, Methylsulfonylmethane, Zinc, Manganese, Copper, Boron
Form Oral tablet
Pharmacological class Nutraceutical Product, Minerals Supplements and Adjuvant Therapy
Common use Supporting joint health and flexibility
Origin Derived (combines naturally sourced and synthesized compounds)

What Type of Combination Supplement is Lubrijoint PLus?

Lubrijoint PLus is categorized as a nutraceutical product and a multi-component nutritional supplement, designed for oral intake in the oral tablet form. This product is generally classified within the group of Minerals Supplements & Adjuvant Therapy, a designation reflecting its role in providing essential nutrients for musculoskeletal health. In many markets, Glucosamine-based products are often regulated and sold as dietary supplements, a category distinct from prescription drugs. The formulation functions as a chondroprotective agent, indicating its purpose is to support the structural health and maintenance of joint cartilage and to provide structural support for joints under mechanical stress.

Core Active Ingredients in the Lubrijoint PLus Formulation

The composition is defined by its two primary active ingredients: the amino sugar derivative Glucosamine Sulfate Potassium Chloride and the organic sulfur compound Methylsulfonylmethane (MSM). Glucosamine serves as a foundational precursor for the biosynthesis of structural components within cartilage. The inclusion of MSM is intended to provide necessary sulfur for the stabilization of connective tissue integrity. The supplement also contains a matrix of mineral cofactors—including Elemental Zinc, Elemental Manganese, Elemental Copper, and Elemental Boron—which are integral to enzyme functions that support the complex processes of bone and cartilage metabolism.

General Purpose and Function for Joint Health

The general purpose of Lubrijoint PLus is to provide the nutritional building blocks required for the body's natural joint maintenance processes, thereby supporting joint resilience in adults. The supportive action of the MSM and the minerals helps maintain the strength and functionality of surrounding connective tissue. This mechanism is designed to promote sustained joint flexibility and mobility by focusing on the physical foundation of the joint system, rather than through temporary symptomatic relief.

Regulatory References

  1. Glucosamine and Chondroitin for Osteoarthritis

What side effects are possible with Lubrijoint PLus?

Possible Side Effects and Safety Information

The safety profile of Lubrijoint PLus is primarily determined by the documented characteristics of its key active ingredients, Glucosamine and Methylsulfonylmethane (MSM), as categorized by government regulatory agencies. Adverse reactions are generally considered Common and transient, with effects largely concentrated in the digestive system.


Adverse Reaction Scope

Classification Examples of Officially Documented Effects
Gastrointestinal Disorders Nausea, heartburn, vomiting, diarrhea, or constipation.
Nervous System Disorders Headache and drowsiness.

Serious Adverse Reactions and Safety Constraints

Regulatory documentation highlights specific, clinically significant safety concerns, which are generally categorized as Rare or arising from post-marketing reports:

  • Hypersensitivity: Documented risk of allergic reactions, including severe manifestations, which is a particular consideration for products sourced from shellfish.
  • Anticoagulant Interaction: Glucosamine and MSM have been noted to potentially increase the effect of certain anticoagulant drugs, such as warfarin, carrying a documented risk for bleeding.
  • Hepatotoxicity: Isolated incidents of liver-related issues have been reported, primarily in individuals with severe pre-existing liver conditions.

Population-Specific Safety Considerations

The official labeling includes specific restrictions for use in certain groups:

  • Contraindications: The product is not to be used by pregnant or breastfeeding women due to the inclusion of components like Boron and insufficient reliable safety data for Glucosamine.
  • Precautions: Caution and monitoring are advised for individuals with diabetes (to monitor blood glucose levels), asthma, and a known shellfish allergy.

Overdose and Emergency Response

Overdose and when to seek help

This section details the officially documented manifestations of overexposure to Lubrijoint PLus components and the regulator-mandated emergency actions.


Documented Manifestations and Serious Outcomes

Overexposure to Glucosamine is officially documented to present with common gastrointestinal symptoms, including nausea, vomiting, diarrhoea, abdominal pain, and constipation. Other documented manifestations may include headache, dizziness, and disorientation, as noted in regulatory literature.

A severe outcome that requires urgent attention is the potential for a severe allergic reaction, marked by signs such as swelling of the face, lips, or throat, and difficult breathing. High intake of the mineral component Zinc is associated with acute toxicity, including the potential for severe kidney injury, specifically Acute Renal Tubular Necrosis and Interstitial Nephritis.


Emergency Actions Required

Immediate medical attention is mandated for any suspected overdose. You must contact a poison control center or emergency room at once based on regulatory instructions. Urgent emergency services must be called if life-threatening symptoms are observed, such as passing out or trouble breathing. Management for overexposure officially consists of discontinuing the supplement and applying symptomatic and standard supportive measures, as no specific antidote is described in regulatory documents. Additionally, closer monitoring of blood sugar levels is required for patients with diabetes in an overdose context.

Therapeutic Uses of Lubrijoint PLus

The fundamental purpose of Lubrijoint PLus is to provide supportive nutritional components for the musculoskeletal system. These ingredients are used for symptomatic relief across key domains, including conditions where functional stability becomes affected.

Supporting Joint Resilience in Degenerative Conditions

This nutraceutical product is used as an adjuvant therapy in clinical situations characterized by conditions presenting with systemic or localized discomfort, such as age-related joint wear. It is relevant when joint function is affected by the gradual breakdown of tissue. By supplying these components, the product supports patients during episodes of heightened discomfort related to structural changes and provides support that helps ease the overall symptom burden associated with long-term wear.

Managing Impaired Mobility and Chronic Stiffness

Lubrijoint PLus is commonly applied in scenarios of functional joint impairment marked by chronic joint stiffness and a diminished range of motion. It is relevant for managing symptoms that interfere with daily comfort. This supportive action may assist with improving joint flexibility and helps improve day-to-day comfort during symptomatic periods.

Targeted Nutritional Support for Active Adults

The supplement is applied in addressing functional instability that may arise over time in patient groups who place regular mechanical stress on their joints, such as physically active individuals, as well as older adults managing natural structural decline. It supports general well-being during symptomatic phases, and may assist with maintaining functional stability.

Quick Fact: Relief for Chronic Joint Stiffness
Primary Therapeutic Goal Support for joint resilience and maintenance of structure-related comfort.
Symptom Relevance Managing symptoms related to impaired joint mobility and reduced range of motion.
Typical User Context Adults seeking long-term maintenance and support against age-related wear.

Regulatory References

  1. NIH National Center for Complementary and Integrative Health (NCCIH) overview on Glucosamine and Chondroitin

Eligibility and Restrictions for Use

Eligibility Profile and Restrictions

Official regulatory documents define strict criteria for using Lubrijoint PLus, based on known contraindications and available clinical data for its primary components.

Eligibility Status Applicable Population or Condition
Contraindicated Patients with a known shellfish allergy or hypersensitivity to any of the product's ingredients.
Allowed Population Adults (18 years and older). Dosage adjustment is generally not required for otherwise healthy older adults.
Not Recommended Children and adolescents under 18 years (safety and efficacy are not established). Pregnant or breastfeeding women (use is not recommended due to insufficient data).
Conditional Use Patients with diabetes or impaired glucose tolerance (requires caution and closer blood sugar monitoring). Individuals with asthma or severe renal or hepatic insufficiency require cautious use and medical supervision.

Lubrijoint PLus is generally intended for use in adults. The most critical exclusion is for patients with an established shellfish allergy, as the active ingredient Glucosamine is frequently derived from crustacean shells. Use is formally not recommended for all pediatric age groups, and during pregnancy and lactation, because official authorities have not established its safety and efficacy for these populations. Specific conditions such as diabetes or organ impairments necessitate caution and medical oversight, as standard usage recommendations may not apply.

What should I know about interactions with other medicines?

The interaction profile for Lubrijoint PLus is based on the official regulatory documentation of its key active components, Glucosamine and Methylsulfonylmethane (MSM). All stated patterns reflect officially reported effects or regulatory restrictions, and are not intended as clinical recommendations.

Documented Drug and Substance Interactions

Interaction Type Interacting Substance or Class Official Regulatory Statement
Pharmacodynamic Potentiation Warfarin (Oral Anticoagulants) Co-administration may potentiate the anticoagulant effect, which is formally evidenced by an increase in the International Normalized Ratio (INR) reported in post-marketing surveillance.
Altered Exposure Tetracycline Glucosamine may increase the gastrointestinal absorption of the medicinal product Tetracycline, potentially altering its systemic exposure.
Metabolic Risk CYP450 Enzymes The active components demonstrate a low potential for pharmacokinetic interaction mediated by major cytochrome P450 enzymes, based on studies cited in government monographs.
Supplement Stacking Manganese-containing Supplements Due to the inclusion of elemental Manganese, caution is required regarding co-administration with other supplements containing this mineral to avoid exceeding officially recognized maximum total daily intake limits.

Interaction-Related Restrictions and Constraints

No mandatory administration separation times are documented in regulatory summaries for the active components. A population-specific note requires caution for individuals with a known Shellfish Allergy, which is related to the commercial sourcing of Glucosamine. This official profile is fundamentally defined by warnings concerning pharmacodynamic potentiation and altered absorption, rather than comprehensive transporter or metabolic interactions.

Mechanism of Action

How Lubrijoint Plus Works

Lubrijoint Plus acts through key mechanistic domains that influence the biochemical and structural balance of articular tissues. Its action focuses on stabilizing the cellular and molecular environment within the articulation.


Modulation of Proteoglycan and Collagen Metabolism

This domain centers on the ingredients' role in affecting the synthesis and degradation of the extracellular matrix components that make up cartilage. The drug modifies early molecular steps by influencing chondrocyte activity, which in turn influences the kinetics of extracellular matrix component synthesis and degradation within the joint.


Regulation of Pro-inflammatory Signaling Pathways

Lubrijoint Plus engages mechanisms that regulate overactive cellular processes by targeting specific receptor- or enzyme-mediated signaling cascades, particularly those involved in the inflammatory response. By modifying these signaling sequences, it results in reduced downstream signaling activity from specific pro-inflammatory mediators within the joint capsule.


Enhancement of Synovial Fluid Viscoelasticity

The drug contains components that directly affect the quality and volume of synovial fluid, the natural lubricant within the joint. This mechanism initiates a sequence that leads to the physical restoration of the fluid’s cushioning properties, promoting the hydrodynamic properties of the synovial fluid and enhancing the capacity of the synovial fluid to absorb mechanical load across the articulating surfaces.

Dosage and Administration Information

How to Use Lubrijoint PLus

The usage protocol for Lubrijoint PLus, a multi-component nutraceutical containing Glucosamine and Methylsulfonylmethane (MSM), is based on established administration patterns for structural joint support in adults.

Administration and Timing

Lubrijoint PLus is administered via the oral route, typically as a tablet or capsule, and is intended for outpatient, self-administered use. The product is swallowed whole with water and should generally be taken with a meal or immediately following food. Taking the supplement with food is a common instruction intended to aid in absorption and minimize potential gastrointestinal discomfort.

Dosing and Duration

Administration is based on a fixed daily dose intended to supply the established target amount of the active ingredients. Clinical patterns frequently use 1500 mg of Glucosamine per day, which may be taken as a single dose or divided into two to three administrations.

Usage is characterized by continuous daily intake over a long-term duration. Since the product supports the structural components of the joint, use is typically maintained over periods exceeding 8 to 12 weeks to observe a potential benefit, rather than being used intermittently or in short, acute cycles. The product is designated for use exclusively in the adult population, with use in pediatric patients not being recommended or established.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lubrijoint PLus


## Research Evidence for Joint Discomfort and Functional Impairment

This section summarizes the structure of Randomized Controlled Trials (RCTs) and systematic reviews that have evaluated the ingredients' use for conditions presenting with joint discomfort, stiffness, and functional limitations, primarily focusing on osteoarthritis of the knee. The core ingredients in Lubrijoint PLus, such as Glucosamine and MSM, were evaluated in numerous clinical trials exploring how symptoms change over time in adults managing conditions marked by functional limitations. These studies research examined the components compared to a placebo (an inactive substance) or to other active treatments.

Research explored measures related to physical discomfort and measures reflecting daily functioning or activity level, specifically using validated questionnaires to track changes in joint pain and stiffness. Findings related to Glucosamine were mixed across high-level reviews. Some trials describing patterns observed in the studies in association with certain specific Glucosamine formulations, while other large, independent studies reported varying results. The overall evidence available is often categorized as having a Low to Moderate level of certainty.


## Long-Term Data and Structural Maintenance Studies

This heading outlines the nature of extended-duration studies and observational cohorts used to assess structural outcomes, such as radiographic changes in the joint space. For chronic joint conditions, studies observing responses over defined time intervals needed to run for years (often 2 to 3 years) because structural changes happen slowly.

Research describes the monitoring of outcomes related to physiological strain or stress, specifically by tracking biomarkers of cartilage turnover and using X-rays to measure the width of the joint space. Some long-term research explored the ingredients' effect on the rate of joint space narrowing. These findings describe group patterns over a period of years, with some studies describing the progression of radiographic joint changes and patterns related to joint space narrowing measures in people taking certain specific Glucosamine formulations.


## What Remains Uncertain About the Research Landscape

This final section synthesizes the key research gaps and unanswered questions documented in the scientific literature. The evidence for structural changes is limited, and findings are often discussed by scientists because the observed changes may be small. Furthermore, comparative evidence is lacking for how the full multi-mineral Lubrijoint PLus combination acts over these multi-year time frames.

Another area of uncertainty is the availability of research data for the multi-mineral matrix (Zinc, Manganese, Copper, Boron) within the full Lubrijoint PLus formulation; data are still emerging for this specific combination in large-scale, long-term RCTs.

Key Studies & References

  1. Glucosamine and Chondroitin for Osteoarthritis: What You Need to Know (NCCIH)
  2. Treatment of osteoarthritis: guideline from the National Institute for Health and Care Excellence (NICE)

Frequently Asked Questions (FAQ)

Common questions about Lubrijoint PLus (FAQ)


Q: How quickly can I expect to notice anything after starting Lubrijoint PLus?

Official usage guidance indicates that because the product supports the structural components of the joint, it is intended for continuous, long-term intake. To observe a potential benefit, usage is typically maintained over periods exceeding 8 to 12 weeks.


Q: How long is a typical course of treatment with Lubrijoint PLus?

The use of Lubrijoint PLus is characterized by continuous daily intake over a long-term duration. Since the product supports the structural components of the joint, treatment is often maintained over periods exceeding 8 to 12 weeks.


Q: Can I use Lubrijoint PLus if I have a liver condition?

Official safety documentation advises that caution and medical supervision are needed for individuals with severe hepatic insufficiency (severe liver impairment). This precaution is included due to isolated post-marketing reports of liver-related issues, primarily in those with severe pre-existing liver conditions.


Q: Is it possible to take Lubrijoint PLus at the same time as my daily vitamins?

Official regulatory documents note a specific caution regarding co-administration with other supplements containing Manganese. This information serves to notify users of potential intake constraints for the mineral, ensuring officially recognized maximum total daily limits are considered.


Q: Does alcohol interact with Lubrijoint PLus?

The official regulatory documentation for Lubrijoint PLus and its components focuses on documented drug and substance interactions. In these profiles, alcohol is not specifically listed as an interacting substance.


Q: Is the research on Lubrijoint PLus considered strong?

The research evidence for the active components in Lubrijoint PLus is often categorized by scientific bodies as having a Low to Moderate level of certainty. Additionally, data for the full multi-mineral combination is limited, particularly regarding long-term, comparative studies.


Q: Is it normal to see no change for the first few weeks of using Lubrijoint PLus?

The usage pattern is consistent with the product's function. Because it is designed to support joint structural components, the official usage protocol involves continuous intake typically exceeding 8 to 12 weeks to observe a potential benefit. Therefore, immediate changes are not the expected outcome.


Q: Can I split or crush the Lubrijoint PLus tablets/capsules?

According to the official administration protocol, Lubrijoint PLus is intended to be swallowed whole with water. The official labeling only specifies swallowing the product whole, and guidance on splitting or crushing is not provided.


Q: How is Lubrijoint PLus metabolized or broken down by the body?

The regulatory documents address the breakdown process by noting that the active components demonstrate a low potential for interaction mediated by major cytochrome P450 enzymes. This enzyme system is the primary metabolic pathway involved in how many substances are processed by the body.


Q: Can Lubrijoint PLus affect my blood pressure?

Official safety summaries for the key component, Glucosamine, indicate that while there was historical concern, most available research suggests that it does not appear to increase blood pressure.


Q: Is Lubrijoint PLus safe to take if I have diabetes?

Official labeling advises caution and monitoring for individuals with diabetes or impaired glucose tolerance. This is due to a theoretical potential for effects on glucose levels, which may require closer blood sugar monitoring.


Q: Are there any reported long-term effects of taking Lubrijoint PLus?

Glucosamine, a key component, is generally considered likely safe in most adults when used continuously for studied long-term periods of up to three years. Safety information focuses on periods studied in clinical research.


Q: Is there a generic version of Lubrijoint PLus available?

Lubrijoint PLus is categorized as a multi-component nutraceutical product and a dietary supplement in many markets. This classification means the product falls outside the regulatory category established for generic prescription medications.


Q: Is Lubrijoint PLus suitable for vegetarians or vegans?

The active ingredient Glucosamine is frequently derived from crustacean shells (shellfish), a factor that affects its suitability for vegetarian and vegan diets. This sourcing information is tied to the official warning for those with shellfish allergies.


Q: Is Lubrijoint PLus effective for all types of joint discomfort?

Research evidence for the product's components has primarily evaluated their use for conditions presenting with joint discomfort and functional limitations. Historically, clinical trials have focused specifically on osteoarthritis of the knee.


Q: Why do some people say Lubrijoint PLus takes a long time to work?

This perception is aligned with the official usage pattern. The product is designed to support the structural components of the joint. Because these changes occur slowly, continuous daily intake maintained over periods exceeding 8 to 12 weeks is required to observe a potential benefit.


Q: Is Lubrijoint PLus approved by the FDA or a similar regulatory body?

Lubrijoint PLus is categorized as a nutraceutical product and dietary supplement in many markets. This classification places it in a category that undergoes regulation as a supplement, which is distinct from the formal approval processes for prescription medications.


Q: Are there restrictions on driving while using Lubrijoint PLus?

The official safety profile for the product lists drowsiness as a possible, generally transient side effect. Due to the presence of this Central Nervous System (CNS) effect, the labeling implies that a user's ability to operate machinery may be affected.


Q: Can I stop taking Lubrijoint PLus suddenly?

The product's safety documentation does not include warnings or precautions about sudden discontinuation or withdrawal symptoms associated with its long-term use, a factor often reserved for certain prescription medications.


Q: Does Lubrijoint PLus contain any ingredients that cause drowsiness?

The product's official safety profile lists drowsiness as a possible, generally transient side effect associated with the use of its active components. This indicates a potential CNS effect from the formulation.


Q: Is Lubrijoint PLus available without a prescription?

Lubrijoint PLus is classified as a nutraceutical product and a multi-component nutritional supplement. This regulatory classification means that in markets where it is sold as a supplement, it is typically available without a prescription.


Q: Does the time of day matter for taking Lubrijoint PLus?

The core administration instruction is to take the product with a meal. However, some authoritative sources report that the MSM component may cause mild stimulation, which could potentially interfere with sleep for some individuals.


Q: What happens in the body when Lubrijoint PLus 'works'?

The product is described as supporting the structural and biochemical balance of joint tissues. Its mechanisms include influencing the production and degradation of cartilage components and engaging pathways that help regulate certain pro-inflammatory signaling within the joint.


Q: Is Lubrijoint PLus designed to replace other joint treatments?

Official guidance for supplements indicates that they are not intended to replace medication or treatments prescribed by a healthcare provider for any medical condition. They are categorized as supportive nutritional products.


Q: Are there known interactions between Lubrijoint PLus and specific food items?

The primary food-related constraint noted in the official profile relates to the sourcing of the ingredient Glucosamine. A critical warning exists for individuals with a known Shellfish Allergy, which is the most critical food-related caution.

How should Lubrijoint PLus be stored and disposed of?

Storage Requirements

Lubrijoint Plus tablets must be stored at room temperature, generally defined as between 15 C and 30 C (59 F and 86 F). The product must be kept in a cool and dry place, protected from excessive heat and direct sunlight.

To ensure tablet integrity, the medicine must be kept in an airtight container and should not be used past the expiry date printed on the label.

Handling and Safety

Official labeling requires that the tablets be kept out of the sight and reach of children to prevent accidental ingestion. It is also advised to keep the product away from pets.

Disposal

No specific disposal instructions for unused or expired Lubrijoint Plus are provided in the official regulatory documents. Disposal should comply with general local guidelines for non-hazardous household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Lubrijoint PLus found in:

A-Z Index: